Kurma Partners

Germitec is a healthcare company focused on developing ultraviolet light disinfection systems aimed at improving hospital hygiene. The company specializes in high-level disinfection using UV-C technology, which is designed to effectively reprocess non-lumen medical devices. By simplifying safety protocols and reducing the time and responsibility of healthcare professionals, Germitec's systems help transform clinical practices and minimize the risk of cross-infection within medical facilities.

Axithra is a company that specializes in therapeutic medication monitoring, specifically focusing on beta-lactam antibiotics. The business has developed a platform that enables rapid and accurate measurement of drug concentrations in the bloodstream, which is essential for personalized treatment in intensive care settings. By utilizing proprietary optical and photonics technology, Axithra's application allows healthcare providers to tailor antibiotic treatments to the individual needs of patients. This innovation aims to enhance patient care by ensuring that drug levels are monitored effectively, facilitating prompt adjustments to optimize therapeutic outcomes.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Sunrise focuses on addressing the widespread issue of sleep disorders, particularly sleep apnea, which affects nearly one billion people globally. The company has developed a 3-gram sensor that provides a rapid, at-home diagnosis of sleep apnea, utilizing trigeminal drive analysis to detect respiratory events. This certified medical device connects seamlessly to a smartphone, allowing for easy use and immediate results. Clinical studies have demonstrated that Sunrise's technology matches the accuracy of traditional in-lab sleep studies but at a significantly lower cost. After testing, patients can consult with certified sleep doctors online or visit local sleep centers, streamlining the diagnostic process. With a large percentage of sleep apnea cases remaining undiagnosed, Sunrise offers a crucial solution for patients, caregivers, and insurers, enhancing the accessibility and efficiency of sleep disorder diagnostics.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Germitec is a healthcare company focused on developing ultraviolet light disinfection systems aimed at improving hospital hygiene. The company specializes in high-level disinfection using UV-C technology, which is designed to effectively reprocess non-lumen medical devices. By simplifying safety protocols and reducing the time and responsibility of healthcare professionals, Germitec's systems help transform clinical practices and minimize the risk of cross-infection within medical facilities.

Sunrise focuses on addressing the widespread issue of sleep disorders, particularly sleep apnea, which affects nearly one billion people globally. The company has developed a 3-gram sensor that provides a rapid, at-home diagnosis of sleep apnea, utilizing trigeminal drive analysis to detect respiratory events. This certified medical device connects seamlessly to a smartphone, allowing for easy use and immediate results. Clinical studies have demonstrated that Sunrise's technology matches the accuracy of traditional in-lab sleep studies but at a significantly lower cost. After testing, patients can consult with certified sleep doctors online or visit local sleep centers, streamlining the diagnostic process. With a large percentage of sleep apnea cases remaining undiagnosed, Sunrise offers a crucial solution for patients, caregivers, and insurers, enhancing the accessibility and efficiency of sleep disorder diagnostics.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

SmartCatch specializes in liquid biopsy technology aimed at enhancing cancer detection and treatment. The company has developed a minimally invasive method to extract circulating tumor cells, offering a series of products focused on the capture and isolation of these cells. This technology provides researchers and clinicians with valuable data that can significantly improve cancer patient outcomes. By empowering the medical community with advanced tools, SmartCatch contributes to the ongoing battle against cancer, facilitating better diagnostic and therapeutic approaches.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Lucine has the ambition to transform and improve patient’s health. Their main therapeutic area is pain. The product, a digital therapeutic is able to relieve patient’s pain in 5 minutes through active substances allowing an analgesic neurostimulation. Customized, their solution is adapted to each patient thanks to an instantaneous measurement and analysis of the pain by facial, vocal and postural recognition.

FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Sensome is a company that specializes in developing innovative remote monitoring technology aimed at transforming invasive vascular medical devices into connected healthcare solutions. Their patent-pending sensor technology utilizes impedance-based micro-sensors combined with machine learning algorithms to provide instantaneous and non-invasive identification of tissue composition in contact with medical devices. This breakthrough addresses the limitations of traditional vascular imaging techniques, enhancing both intervention procedures and patient follow-up. Currently, Sensome's team is focused on creating vascular access devices integrated with this proprietary sensor technology, with future plans to equip implantable devices for various medical applications, including neurovascular, peripheral vascular, and cardiovascular fields.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Sensome is a company that specializes in developing innovative remote monitoring technology aimed at transforming invasive vascular medical devices into connected healthcare solutions. Their patent-pending sensor technology utilizes impedance-based micro-sensors combined with machine learning algorithms to provide instantaneous and non-invasive identification of tissue composition in contact with medical devices. This breakthrough addresses the limitations of traditional vascular imaging techniques, enhancing both intervention procedures and patient follow-up. Currently, Sensome's team is focused on creating vascular access devices integrated with this proprietary sensor technology, with future plans to equip implantable devices for various medical applications, including neurovascular, peripheral vascular, and cardiovascular fields.

Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatment. Established in 2010, the company offers a range of products including the SteriSpine PS kit for spinal fractures and degenerative pathologies, the SteriSpine VA platform for Kyphoplasty and Cement systems, and instrumentation for lumbar and cervical cages, including Cedar, Elm, and Walnut models. Safe Orthopaedics aims to enhance surgical outcomes through its innovative solutions in spinal surgery, catering to both domestic and international markets.

Vivet Therapeutics SAS is a biotechnology company focused on researching, developing, and commercializing gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016 and based in Paris, France, the company employs a liver-targeting adeno-associated virus (AAV) vector to deliver therapeutic genes directly into hepatocytes, addressing genetic disorders at their source. Vivet is particularly known for its work on diseases such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I. In collaboration with the Fundacion para la Investigacion Medica Aplicada and the Centro de Investigación Medica Aplicada at the University of Navarra, Vivet aims to enhance gene delivery technologies and ensure long-term expression of therapeutic genes, thereby advancing the field of gene therapy for liver-related conditions.

Damae Medical is a medtech company based in Paris, France, specializing in innovative imaging technology for the medical field. The company has developed a device that allows for in-vivo imaging of biological tissues at a cellular level. This technology enables dermatologists to assess the malignancy of tumors quickly and efficiently through simple contact with the skin's surface, eliminating the need for tissue excision and processing. By providing cellular-resolution imaging similar to traditional histology, Damae Medical aims to enhance skin cancer diagnosis and facilitate immediate, non-invasive assessments for healthcare professionals. The company's mission focuses on leveraging bio-photonics to create new opportunities in medical imaging and diagnostics.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon, France, specializing in the development and manufacturing of innovative patient monitoring systems. The company is dedicated to providing clinicians with critical indicators of tissue perfusion, which are essential for assessing patient health. One of its key products, the IKORUS® monitoring system, addresses a significant gap in the market by enabling early detection of microcirculatory alterations. This advancement allows physicians to explore new investigative fields and improve existing therapeutic practices. The monitoring system is specifically designed to assess intestinal tissue perfusion, guiding novel circulatory therapies and enhancing resuscitation strategies, ultimately aiming to reduce patient complications and treatment costs.

STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through the development of digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling remote monitoring of continuous electrophysiological signals, BioSerenity aims to optimize patient care pathways in cardiology, neurology, and sleep disorders. The data collected from these devices, once anonymized, will be made available to researchers at the Institut du Cerveau et de la Moelle épinière, contributing to advancements in epilepsy research and improving diagnostic methods for the future.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon, France, specializing in the development and manufacturing of innovative patient monitoring systems. The company is dedicated to providing clinicians with critical indicators of tissue perfusion, which are essential for assessing patient health. One of its key products, the IKORUS® monitoring system, addresses a significant gap in the market by enabling early detection of microcirculatory alterations. This advancement allows physicians to explore new investigative fields and improve existing therapeutic practices. The monitoring system is specifically designed to assess intestinal tissue perfusion, guiding novel circulatory therapies and enhancing resuscitation strategies, ultimately aiming to reduce patient complications and treatment costs.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.

Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatment. Established in 2010, the company offers a range of products including the SteriSpine PS kit for spinal fractures and degenerative pathologies, the SteriSpine VA platform for Kyphoplasty and Cement systems, and instrumentation for lumbar and cervical cages, including Cedar, Elm, and Walnut models. Safe Orthopaedics aims to enhance surgical outcomes through its innovative solutions in spinal surgery, catering to both domestic and international markets.